Literature DB >> 23569124

MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review.

Guangxin Zhou1, Xin Shi, Junfeng Zhang, Sujia Wu, Jianning Zhao.   

Abstract

Osteosarcoma is a primary malignant bone tumour with high morbidity that occurs mainly in children and adolescents. While the molecular basis of osteosarcoma has received considerable attention, the cellular and molecular mechanisms underlying pre- and postoperative metastasis formation and the development of chemoresistance remain unclear. MicroRNAs (miRNAs), a class of 22-nucleotide noncoding RNAs, have emerged as critical components of gene-regulatory networks controlling numerous important pathophysiological processes, including the initiation and progression of cancers. Studies on miRNAs have opened new avenues for both the diagnosis and treatment of cancer. This review discusses the roles of miRNAs in osteosarcoma and their potential applications for the diagnosis, prognosis and treatment of this malignancy. As a rapidly evolving field of basic and biomedical science, miRNA research will have a revolutionary impact on the management of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23569124     DOI: 10.1177/0300060513475959

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  27 in total

Review 1.  Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Authors:  Jonathan A R Gordon; Martin A Montecino; Rami I Aqeilan; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

2.  Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma.

Authors:  Yuan Wang; Lian-Shun Jia; Wen Yuan; Zhao Wu; Hai-Bo Wang; Tao Xu; Jing-Chuan Sun; Ke-Fu Cheng; Jian-Gang Shi
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

3.  Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.

Authors:  Yisila Mu; Haoshaqiang Zhang; Lixin Che; Kun Li
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

Review 4.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 5.  The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease.

Authors:  Catarina Melim; Ivana Jarak; Francisco Veiga; Ana Figueiras
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

6.  Physico-chemical fingerprinting of RNA genes.

Authors:  Ankita Singh; Akhilesh Mishra; Ali Khosravi; Garima Khandelwal; B Jayaram
Journal:  Nucleic Acids Res       Date:  2017-04-20       Impact factor: 16.971

7.  Differential expression of AURKA/PLK4 in quiescence and senescence of osteosarcoma U2OS cells.

Authors:  Xiao-Liang Xie; Hai-Xia Zhu; Yu-Mei Li; De-Ta Chen; Tian-You Fan
Journal:  Cell Cycle       Date:  2020-03-21       Impact factor: 4.534

8.  Identification and validation of microRNAs and their targets expressed in osteosarcoma.

Authors:  Can Zhang; Jun Wan; Feng Long; Qing Liu; Hongbo He
Journal:  Oncol Lett       Date:  2019-09-13       Impact factor: 2.967

9.  MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1.

Authors:  Dengkun Lv; Zhen Zhen; Defa Huang
Journal:  Exp Ther Med       Date:  2018-11-29       Impact factor: 2.447

10.  Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a.

Authors:  De-Qiu Zhu; Yue-Fen Lou; Zhi-Gao He; Min Ji
Journal:  Tumour Biol       Date:  2014-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.